Anti-angiogenic agents target various regulators engaged in tumor angiogenesis (i.e., VEGF, fibroblast growth factor (FGF), PDGF, epidermal growth factor (EGF), TGF-β, HIF1, NF-κB, MMPs, and integrins), with the VEGF and its receptor VEGFR signaling pathway playing a dominant role in this process [359]. The gene discussed is KDR; the disease is neoplasm.